Evidence map›Paper›PMID 37463491›Full record

ArticleACS nano2023

Immunomodulatory Effects of Subacute Inhalation Exposure to Copper Oxide Nanoparticles in House Dust Mite-Induced Asthma.

Sudartip Areecheewakul, Andrea Adamcakova-Dodd, Zeb R Zacharias, Xuefang Jing, David K Meyerholz, Kevin L Legge, Jon C D Houtman, Patrick T O'Shaughnessy, Peter S Thorne, Aliasger K Salem

Open access · hybridAbstract read
In one paragraph

Article in ACS nano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Nanoparticles to target asthma.American journal of physiology. Lung cellular and molecular physiology · 2024
    Review
  5. Article
  6. The roles of essential trace elements in T cell biology.Journal of cellular and molecular medicine · 2024
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sudartip AreecheewakulDepartment of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, Iowa 52242, United States.
Andrea Adamcakova-DoddDepartment of Occupational and Environmental Health, University of Iowa, Iowa City, Iowa 52242, United States.ORCID 0000-0002-0570-239X
Zeb R ZachariasInterdisciplinary Immunology Graduate Program, Department of Pathology, University of Iowa, Iowa City, Iowa 52242, United States.
Xuefang JingDepartment of Occupational and Environmental Health, University of Iowa, Iowa City, Iowa 52242, United States.
David K MeyerholzDepartment of Pathology, University of Iowa, Iowa City, Iowa 52242, United States.
Kevin L LeggeInterdisciplinary Immunology Graduate Program, Department of Pathology, University of Iowa, Iowa City, Iowa 52242, United States.
Jon C D HoutmanDepartment of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, United States.
Patrick T O'ShaughnessyDepartment of Occupational and Environmental Health, University of Iowa, Iowa City, Iowa 52242, United States.
Peter S ThorneDepartment of Occupational and Environmental Health, University of Iowa, Iowa City, Iowa 52242, United States.ORCID 0000-0002-5045-0929
Aliasger K SalemDepartment of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, Iowa 52242, United States.ORCID 0000-0002-1923-6633
University of Iowa · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Brandi Janssen · 1990 to 2026
$40.5M
Engineered Nanomaterial Synthesis, Characterization and Method Development Center for Nano-safety ResearchU24ES026946 · NIEHS · HARVARD SCHOOL OF PUBLIC HEALTH · PI DEMOKRITOU, PHILIP · 2016 to 2020
$3.8M
Immunomodulation Potential of Inhaled Engineered Nanomaterials as an Adverse Outcome PathwayU01ES027252 · NIEHS · UNIVERSITY OF IOWA · PI THORNE, PETER S · 2016 to 2020
$2.1M
NCI NIH HHS P30 CA086862NIEHS NIH HHS P30 ES005605NIEHS NIH HHS U01 ES027252NIEHS NIH HHS U24 ES026946
6 · The paper itself

Abstract

It has been shown that inhalation exposure to copper oxide nanoparticles (CuO NPs) results in pulmonary inflammation. However, immunomodulatory consequences after CuO NP inhalation exposure have been less explored. We tested the effect of CuO NP aerosols on immune responses in healthy, house dust mite (HDM) asthmatic, or allergen immunotherapy (AIT)-treated asthmatic mice (BALB/c, females). The AIT consisted of a vaccine comprising HDM allergens and CpG-loaded nanoparticles (CpG NPs). AIT treatment involved mice being immunized (via subcutaneous (sc) injection; 2 doses) while concomitantly being exposed to CuO NP aerosols (over a 2 week period), starting on the day of the first vaccination. Mice were then sensitized twice by sc injection and subsequently challenged with HDM extract 10 times by intranasal instillation. The asthmatic model followed the same timeline except that no immunizations were administered. All mice were necropsied 24 h after the end of the HDM challenge. CuO NP-exposed healthy mice showed a significant decrease in T

Indexed as

AsthmaNanoparticlesAnimalsCopperFemaleImmunityInhalation ExposureMiceOxidesPyroglyphidaeCoppercupric oxidecuprous oxideOxidescopper oxidehouse dust mite asthma modelimmunomodulatory effectsimmunotherapyinhalationnanoparticlespulmonary toxicity

Identifiers

PMID37463491
PMCPMC10416562
OpenAlexW4384662915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.